Dublin, April 16, 2018 -- The "Global Stem Cell Partnering 2010-2018: Deal trends, players, financials and forecasts" report has been added to ResearchAndMarkets.com's offering.
The Global Stem Cell Partnering 2010-2018: Deal trends, players, financials and forecasts report provides comprehensive understanding and unprecedented access to the stem cell partnering deals and agreements entered into by the worlds leading healthcare companies. This report provides details of the latest Stem Cell agreements announced in the life sciences since 2010.
The report provides a detailed understanding and analysis of how and why companies enter Stem Cell partnering deals. These deals tend to be multicomponent, starting with collaborative R&D, and proceed to commercialization of outcomes.
The report takes the reader through a comprehensive review Stem Cell deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Stem Cell partnering deals.
The report presents financial deal term values for Stem Cell deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals.
Key benefits
- In-depth understanding of Stem Cell deal trends since 2010
- Access to headline, upfront, milestone and royalty data
- Analysis of the structure of Stem Cell agreements with numerous real life case studies
- Detailed access to actual Stem Cell contracts entered into by leading biopharma companies
- Identify most active Stem Cell dealmakers since 2010
- Insight into terms included in a Stem Cell partnering agreement, with real world examples
- Understand the key deal terms companies have agreed in previous deals
- Undertake due diligence to assess suitability of your proposed deal terms for partner companies
Stem Cell Partnering Terms and Agreements includes:
- Trends in Stem Cell dealmaking in the biopharma industry since 2010
- Analysis of Stem Cell deal structure
- Access to headline, upfront, milestone and royalty data
- Case studies of real-life Stem Cell deals
- Access to Stem Cell contract documents
- Leading Stem Cell deals by value since 2010
- Most active Stem Cell dealmakers since 2010
Available deals are listed by:
- Company A-Z
- Headline value
- Stage of development at signing
- Deal component type
- Specific therapy target
- Technology type
Key Topics Covered:
Executive Summary
Chapter 1 - Introduction
Chapter 2 - Trends in Stem Cell dealmaking
Chapter 3 - Leading Stem Cell deals
Chapter 4 - Most active Stem Cell dealmakers
Chapter 5 - Stem Cell contracts dealmaking directory
Chapter 6 - Stem Cell dealmaking by technology type
Chapter 7 - Partnering resource center
For more information about this report visit https://www.researchandmarkets.com/research/bmcg8z/global_stem_cell?w=12
CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Stem Cells


Russia Moves to Fully Block WhatsApp as Kremlin Pushes State-Backed MAX App
Xiaomi EV Deliveries Surpass 600,000 Units as SU7 and YU7 Drive Strong Growth
Novocure Stock Surges 30% After FDA Approves Optune Pax for Pancreatic Cancer Treatment
GE Aerospace Expands Singapore Engine Repair Hub with Automation and AI to Tackle Aviation Bottlenecks
U.S. Commerce Department Reaches $252 Million Settlement With Applied Materials Over China Exports
Michael Kors Marks 45 Years at New York Fashion Week with Fall/Winter Collection Showcase
Air New Zealand Cabin Crew Strike Set for February 12–13 Amid Failed Talks
CBA Shares Surge After Record Half-Year Profit as Rate Outlook Improves
Boeing Reports Major Supply Chain Quality Improvements After Spirit AeroSystems Deal
AbbVie Sues HHS Over Medicare Price Controls on Botox Under Inflation Reduction Act
Gates Foundation Denies Financial Ties to Jeffrey Epstein Following DOJ Email Release
Novartis’ Vanrafia Shows Strong Phase 3 Results in IgA Nephropathy, Paving Way for Full Approval
U.S. Judge Allows Jeffrey Epstein Sex Trafficking Lawsuit Against Bank of America to Proceed
Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan
Vale Reports $3.8 Billion Q4 Net Loss Amid Nickel Asset Impairment and Samarco Provisions
ByteDance Advances AI Chip Development With Samsung Manufacturing Talks
Instagram CEO Defends Platform in Youth Mental Health Lawsuit Over Social Media Addiction Claims 



